Los puntos clave no están disponibles para este artículo en este momento.
The combination of galunisertib and sorafenib showed acceptable safety and a prolonged OS outcome.
Kelley et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: